In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6M0J)

In this study, FDA-approved HCV antiviral drugs and their structural analogues—several of them in clinical trials—were tested for their inhibitory properties toward the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (6M0J) using a virtual screening approach and computational chemi...

Descripción completa

Detalles Bibliográficos
Autor principal: Kalamatianos, Konstantinos G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223260/
https://www.ncbi.nlm.nih.gov/pubmed/35739375
http://dx.doi.org/10.1007/s11030-022-10469-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223260/
https://www.ncbi.nlm.nih.gov/pubmed/35739375
http://dx.doi.org/10.1007/s11030-022-10469-7

Ejemplares similares